This study tested a PARP inhibitor; the registry lists it as terminated.
The registry listed NCT06930755 as recruiting when this summary was written; read again on 17 November 2026 (record updated 2026-11-16), it lists the study as terminated, a decision the sponsor says was strategic and not based on safety or clinical data. Enrolment is 24 planned participants, an estimate. Interventions: NMS-03305293, Topotecan. Primary measures include Number of Participants with Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-11-17. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/